Compared with other treatment groups, the CP@NP-cRGD and AZD9291 group exhibited the slowest tumor growth curves and showed the strongest antitumor effect (Figure 6g), suggesting that CP@NP-cRGD could effectively surmount drug resistance to AZD9291 in vivo. Here, CP is linked to neoplasm.